Academic
Publications
Complete remission of primary plasma cell leukemia with bortezomib, doxorubicin, and dexamethasone: a case report

Complete remission of primary plasma cell leukemia with bortezomib, doxorubicin, and dexamethasone: a case report,10.1186/1757-1626-2-121,Cases Journa

Complete remission of primary plasma cell leukemia with bortezomib, doxorubicin, and dexamethasone: a case report   (Citations: 2)
BibTex | RIS | RefWorks Download
BACKGROUND: Plasma cell leukemia (PCL) is a rare lymphoproliferative disorder considered to be a variant of multiple myeloma. It is an aggressive disease with a poor clinical response to standard chemotherapeutic agents. CASE PRESENTATION: A novel regimen consisting of bortezomib, doxorubicin, and dexamethasone is currently under active evaluation for the treatment of multiple myeloma. We employed this combination as front-line chemoinduction therapy for a case of primary PCL. CONCLUSION: Complete remission was achieved with rapid normalization of hematologic parameters. The combination of bortezomib, doxorubicin and dexamethasone demonstrates promise in the treatment of PCL.
Journal: Cases Journal - Cases J , vol. 2, no. 1, 2009
Cumulative Annual
View Publication
The following links allow you to view full publications. These links are maintained by other sources not affiliated with Microsoft Academic Search.
Sort by: